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Background: Alpha-1-antitrypsin (AAT) deficiency increases the risk of emphysema, especially
in smokers. In 1972e1974, all 200,000 Swedish new-born infants were screened for AAT defi-
ciency and individuals with severe (PiZZ) and moderate (PiSZ) deficiency have been
followed-up regularly. The aim of the present study was to examine their lung function at
the age of 30 years, comparing them to a group of age-matched control subjects (PiMM)
recruited from the general population, and to compare current smokers with never-smokers.
Method: Static and dynamic spirometry, including TLC, FRC, RV, VC, FEV1, KCO and DL,CO, was
performed for all participants. All values were expressed as percentages of the expected
values. FEV1/VC was expressed both as percentage of the expected value and in absolute
numbers.
Results: Four of 60 PiZZ, none of 19 PiSZ and 9 of 33 PiMM participating individuals were
current smokers. All Pi groups had a normal mean FEV1. The mean (SD) FEV1/VC ratio was
75% (7.4) in the PiZZ smokers and 84% (5.5) in the PiZZ never-smokers (p < 0.01). The mean
(SD) KCO was 81 (13) in the PiZZ smokers and 99 (14) in the PiZZ never-smokers (p < 0.05).
Conclusion: AAT-deficient individuals identified by neonatal screening have normal lung func-
tion at the age of 30. The PiZZ smokers had changes in lung function that may be signs of early
emphysema.
ª 2009 Elsevier Ltd. All rights reserved.(0)40 331000, þ46 (0)70
g@med.lu.se (E. Bernspa˚ng).
9 Elsevier Ltd. All rights reservedIntroduction
Alpha-1-antitrypsin (AAT) is primarily synthesized in the
liver. Its major function is to protect lung tissue elastin
from neutrophil elastase-mediated destruction by irre-
versibly binding and inhibiting elastase.1 AAT-deficient
individuals have various degrees of loss of function.
Table 1 Response frequency, gender ratio, age and
smoking history in the three Pi groups.
PiZZ
(nZ 60)
PiSZ
(nZ 19)
PiMM
(nZ 33)
Gender, n (%) female 24 (40) 9 (47) 17 (52)
Age, years 31 (30e33) 31 (28e33) 31 (30e32)
Smoking habits
Current smokers, n (%) 4 (7) 0 (0) 9 (27)
Ex-smokers, n (%) 4 (7) 3 (16) 4 (12)
Never-smokers, n (%) 52 (87)a 16 (84) 20 (61)y
Number of pack-
years in
ever-smokers
4.6
(0.4e8.1)
5.8
(1.5e12.0)
7.3
(0.2e17.8)
Age at which
ex-smokers quit
22 (16e27) 23 (20e27) 23 (14e29)
Age, pack-years and age when quitting are expressed as mean
(range).
y p < 0.05 compared to all AAT-deficient subjects.
a The sum of percentages in the PiZZ group does not equal 100
due to rounding up.
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AAT deficiency (PiZZ) increases the risk of developing
emphysema and in PiZZ smokers, emphysema may occur as
early as in the fourth decade of life2 but the natural history
of lung disease in AAT deficiency is still incompletely
known. As for emphysema and chronic obstructive pulmo-
nary disease (COPD) in general, dyspnoea is often the first
symptom in patients with severe AAT deficiency, while
wheezing has been shown to predict a decrease in lung
function.3
The individuals with severe (PiZZ) and moderate (PiSZ)
AAT deficiency in this study were identified in the Swedish
neonatal AAT screening of 19721974.4 The aim was to
investigate the lung function in this cohort at 30 years of
age, to compare with an age-matched control group (PiMM)
from the general population, and to investigate whether
pulmonary function within the cohort differs between
smokers and non-smokers.
Material and methods
Subjects
From November 1972 until September 1974, all 200,000
Swedish new-born infants were screened for AAT defi-
ciency, and 127 PiZZ, 54 PiSZ, 2 PiZ and 1 PiS subjects
were identified. Five PiZZ children died early and four PiZZ
individuals have been included after the screening. The
present cohort of 128 PiZ (including two PiZ) and 55 PiSZ
(including one PiS) AAT-deficient, 30-year-old individuals
were invited to undergo pulmonary function tests at the
Department of Clinical Physiology at the University
Hospital, Malmo¨ or at their local hospital.
Of 300 randomly selected control subjects from the
Swedish population registry, 90 individuals had visited the
Department of Respiratory Medicine, University Hospital,
Malmo¨, for a previous study.5 The control subjects were
tested for AAT and six individuals, found to be heterozy-
gotes, PiMZ, were excluded from further analysis. The
remaining 84 PiMM subjects were invited to undergo
pulmonary function tests at the Department of Clinical
Physiology at the University Hospital in Malmo¨.
Information about smoking habits, including number of
cigarettes per day and years of smoking, as well as records
of wheezing and breathlessness, for all participants were
obtained from a questionnaire, collected as previously
reported.5
The study was conducted in accordance with the Hel-
sinki Declaration, and approved by the Regional Ethical
Review Board of Lund University, Sweden. All participants
in the study gave their signed, informed consent.
Pulmonary function tests
Examinations were requested to be done according to
a protocol, which included static and dynamic spirometry,
i.e. total lung capacity (TLC), functional residual capacity
(FRC), residual volume (RV) and diffusing capacity for
carbon monoxide (DL,CO), including transfer coefficient
(KCO), forced expiratory volume in one second (FEV1) and
vital capacity (VC). FEV1 and VC were measured before and15 min after bronchodilation with either 1.0 mg terbutaline
or 0.4 mg salbutamol. TLC and RV were measured in the
majority of cases with body plethysmography, while the gas
dilution technique was used in some subjects. Lung func-
tion tests, including calibration of the equipment, were
performed according either to the European Respiratory
Society (ERS) guidelines (the majority of cases, and
including the examinations done in Malmo¨),6 or to the
American Thoracic Society (ATS) guidelines (few cases).7
Pulmonary function variables are expressed as percent-
ages of the expected values and are computed using the
European Coal and Steel Community summary equations.8
When not otherwise indicated, values after bronchodilation
are reported, i.e. for VC, FEV1 and FEV1/VC. FEV1/VC is
expressed both as percentage of the expected value and in
absolute numbers (FEV1/VC ratio).
Comparison of the results of the pulmonary function
tests was made between the Pi subgroups and between the
smoking subgroups, i.e. current, ex- and never-smokers.
Statistical analysis
Statistical analyses were carried out using SPSS 12.0.1
software. Continuous variables were analysed with ANOVA.
The c2-test was used to analyse categorical values. Testing
for normal distribution was done using the ShapiroeWilks
test.
Results
Participation and smoking history
The number of participants, their age and smoking history
are presented in Table 1. Sixty of the 126 PiZZ, none of the
2 PiZ, 19 of 55 the PiSZ and 33 of the 294 control subjects
underwent pulmonary function tests. There was no signifi-
cant difference in age between the AAT-deficient and the
Table 3 Results of pulmonary function tests in PiZZ and
PiMM current and never-smokers.
PiZZ PiMM
Current
smokers
(nZ 4)
Never-
smokers
(nZ 52)
Current
smokers
(nZ 9)
Never-
smokers
(nZ 20)
FEV1 109 (15) 110 (13) 103 (14) 107 (9.9)
VC 126 (7.8)y,z 111 (15) 107 (11) 110 (8.7)
FEV1/VC 91 (9)* 102 (6) 99 (9) 101 (4)
FEV1/VC
ratio, %
75 (7.4)* 84 (5.5) 81 (8.2) 83 (3.5)
TLC 116 (15)z 105 (13) 102 (8.1) 103 (6.5)
FRC 112 (19) 106 (20) 98 (21) 98 (19)
RV 104 (30) 101 (22) 99 (16) 100 (24)
DL,CO 82 (8.9) 91 (12) 86 (13) 91 (12)
KCO 81 (13)
y 99 (14) 91 (9.4) 97 (13)
Pulmonary function values, except FEV1/VC ratio, are
expressed as % of predicted values. All values are means (SD).
VC, FEV1 and FEV1/VC represent values after bronchodilation.
FEV1, forced expiratory volume in one second; VC, vital
capacity; TLC, total lung capacity; FRC, functional residual
capacity; RV, residual volume; DL,CO, diffusion capacity; KCO,
diffusion constant.
* p < 0.01 compared to PiZZ never-smokers
y p < 0.05 compared to PiZZ never-smokers
z p < 0.05 compared to PiMM current smokers.
Lung function in AAT deficiency 863control subjects. A higher proportion of the control group
had smoked than of the AAT-deficient individuals (p < 0.05)
and there were more current smokers in the control group
(p < 0.01) but the difference in the number of pack-years
between the groups was not significant.
Pulmonary function tests
The results of the pulmonary function tests are shown in
Table 2. Due to the small numbers of participants data are
presented as means (SD). However, despite the small
numbers, normal distribution could not be rejected, and for
this reason parametric tests were used.
When comparing the Pi subgroups as a whole the only
statistically significant difference was found in FRC when
comparing the PiZZ and the PiSZ subgroups. Otherwise, no
statistically significant differences were found in pulmo-
nary function parameters. The results of the PiZZ and PiMM
current and never-smokers are shown in Table 3. The PiZZ
current smokers had significantly higher mean VC and TLC
than the PiMM smokers (p < 0.05), and higher VC compared
to the VC of the PiZZ never-smokers (p < 0.05). They also
had a lower FEV1/VC ratio (p < 0.01; Fig. 1) and KCO
(p < 0.05; Fig. 2) than the PiZZ never-smokers. Compared
to the PiZZ never-smokers, in the PiZZ current smokers
there was a trend towards a higher FRC and RV but the
differences were not statistically significant. There were no
significant differences in FEV1, nor in the prevalence of
respiratory symptoms, in the current PiZZ smokers
compared to the PiZZ never-smokers or the PiMM current
smokers. The results of the lung function tests in the PiZZ
ex-smokers did not differ significantly from the results in
the current and never-smokers (data not shown).
Thirty of the PiZZ and eight of the PiSZ individuals were
examined at their local hospital. Their results did not differ
from those examined in Malmo¨, except that the PiSZ
subjects examined at the local hospitals, had a statisticallyTable 2 Results of pulmonary function tests in the Pi
subgroups.
PiZZ PiSZ PiMM
All, n 60 19 33
FEV1 110 (14) 109 (13) 107 (11)
VC 112 (14) 112 (12) 110 (9.4)
FEV1/VC 101 (7) 101 (7) 100 (6)
FEV1/VC ratio, % 83 (5.9) 83 (6.1) 83 (5.1)
TLC 106 (13) 104 (10) 103 (6.7)
FRC 106 (19)* 93 (16) 98 (19)
RV 101 (22) 92 (14) 98 (21)
DL,CO 90 (12) 89 (15) 89 (12)
KCO 97 (14) 96 (13) 94 (12)
Pulmonary function values, except FEV1/VC ratio, are
expressed as % of predicted values. All values are means (SD).
VC, FEV1 and FEV1/VC represent values after bronchodilation.
FEV1, forced expiratory volume in one second; VC, vital
capacity; TLC, total lung capacity; FRC, functional residual
capacity; RV, residual volume; DL,CO, diffusion capacity; KCO,
diffusion constant.
* p < 0.05 compared to PiSZ,significant lower mean KCO (SD) (local hospital: 89 (15)%
predicted; Malmo¨: 101 (9.3)% predicted). This did not apply
to the PiZZ subgroup. There were no significant differences
in number of current and ex-smokers examined in Malmo¨
compared to local hospitals (data not shown).
Two PiZZ, one PiSZ and one PiMM subject had a positive
reversibility in FEV1 of 12% and 200 ml or more (not signif-
icant); all these were never-smokers. No participants in any
Pi group had a FEV1 lower than 80% of the predicted value
after bronchodilation. One never-smoking PiSZ and one
currently-smoking PiMM individual had a FEV1/VC ratio
below 70% and one PiZZ, currently-smoking subject hadPiZZ Current PiZZ Never PiMM Current PiMM Never
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Figure 1 The FEV1/VC ratios in PiZZ and PiMM current and
never-smokers. The means are indicated by horizontal bars.
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Figure 2 KCO in PiZZ and PiMM current and never-smokers.
The means are indicated by horizontal bars.
864 E. Bernspa˚ng et al.exactly 70% after bronchodilation (Fig. 1). One never-
smoking PiSZ, two never-smoking and one current smoking
PiZZ individual had a KCO of less than 70% of the predicted
value (Fig. 2).
Discussion
Our results show that the four PiZZ current smokers had
a significantly lower mean KCO and FEV1/VC ratio than the
PiZZ never-smokers, which may be a sign of incipient
emphysema. In addition, they had increased VC, TLC and
FRC and decreased diffusing capacity for carbon monoxide,
although only VC and TLC reached statistical significance,
when compared to the PiMM current smokers. Because no
current smokers with the phenotype PiSZ participated in
the study it remains unclear whether PiSZ smokers would
have signs of impaired lung function. However, our results
confirm that non-smoking PiZZ and PiSZ individuals still
have normal mean lung function parameters at the age
of 30.
Spirometry, including FEV1 and FVC, has been performed
every fourth year in this cohort and the results have shown
normal mean pulmonary function in both smokers and non-
smokers at 22, 26 and 30 years of age.5,9,10 Though several
lung function parameters were altered in the current
smokers in this study, the mean FEV1 was normal. The
increased VC and TLC in the PiZZ smokers in this study may
be explained by loss of lung elastic recoil in lung paren-
chyma as described by Corbin et al. in a four-year follow-up
study of lung mechanics in AAT-replete smokers.11
One of the lung function parameters that was impaired
was DL,CO. Decreased DL,CO is considered to correlate with
dyspnoea,12 a prominent symptom in COPD associated with
AAT deficiency.13 DL,CO decreases as emphysema prog-
resses.14 In the previous follow-ups of the cohort the PiZZ
smokers have reported increased dyspnoea on exertion5,9,10
and it is possible that increased dyspnoea in smokers was
caused by impaired gas transfer which cannot be detected
by measurement of FEV1.
The number of ever-smokers among the AAT-deficient
individuals was small. In the different Pi subgroups, themost recent ex-smokers had stopped smoking four to two
years prior to the examination (Table 2). Their lung func-
tion did not differ from the never-smokers (data not
shown), thus we focused on the current smokers in order to
identify early signs of COPD. Of the 107 PiZZ individuals
answering the questionnaire, seven reported current
smoking,5 and only four of them participated in this study.
The control group, a random sample from the pop-
ulation in the Region of Ska˚ne in southern Sweden,
included significantly more ever-smokers than the group of
AAT-deficient individuals. Expressed in number of pack-
years, the control ever-smokers had smoked more than the
AAT ever-smokers, although the difference was not statis-
tically significant (Table 2). Because the proportion of
smokers in the control group was higher than in the PiZZ
subgroup, the power of the statistical analysis to detect
changes in lung function in the PiMM smokers should be
higher than in the PiZZ smokers. The fact that no signifi-
cant changes were found between the nine PiMM smokers
and the 20 PiMM never-smokers may indicate that they are
less vulnerable to lung function impairment than the PiZZ
smokers.
The smoking frequency of 27% in the control group was
higher than in the general population in this region, where
approximately one of five people smokes.15 A higher rate of
smoking participants compared to the general population
has been reported in the European Community Respiratory
Health Study (ECRHS).16 This may be due to smokers being
more concerned about their health and thus are more likely
to participate in health surveys.
Just over 10% of the control subjects and fewer than half
of the AAT-deficient individuals underwent lung function
tests. As a group, healthy control subjects were not easy to
enrol. They were at first invited to participate in our
previous study on respiratory symptoms and lung function
at the age of 30.5 Of the 300 control subjects who were
invited to participate, 84 PiMM subjects visited the
hospital. Of these, 33 agreed to participate in the present
study. The most common reasons for not participating were
lack of time and lack of interest, as described in the
previous publication.5 The AAT-deficient subjects had the
same reasons for not participating. The difficulty in
enrolling participants has also been reported in other
Swedish studies.17,18
In addition to the low participation rate, the use of
different equipment for pulmonary function tests at the
local hospitals may be a source of weakness in this study.
However, without the possibility to be examined at their
local hospital, further individuals in the cohort would deny
participation. When comparing those examined in Malmo¨
and those examined at the local hospitals, the only signif-
icant difference was found in the PiSZ subgroup for KCO.
Since the larger group of PiZZ individuals did not show any
differences it is unlikely that the use of different equip-
ment had a significant impact on the results, thus no
further correction was made for this. Since the proportion
of smokers in Malmo¨ was about the same as at the other
hospitals, the possible effect of smoking habits could be
neglected.
In conclusion, in this cohort of AAT-deficient individuals,
the PiZZ smokers have changes in lung function that may be
a sign of early emphysema.
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